维普期刊资源整合服务平台（V6.5）

503篇 您的检索式：作者名="BARLOGIE B"

选中清除导出查看参考文献查看引证文献引用追踪共26页首页上一页第1页下一页末页 /26 跳转

	题名	作者	年代	出处	被引量
1	Thalidomide in the management of multiple myeloma显示文摘	Barlogie B Zangari M Spencer T		0，，：	2
2	A phase 2 study of bortezomib in relapsed, refractory myeloma 显示文摘	Richardson P G Barlogie B Berenson J	2003	N Engl J Med2003，348，26：	1
3	A new staging sys- tem for multiple myeloma patients based on the Southwest On- cology Group (SWOG) experience 显示文摘	Jaeobson JL Hussein MA Barlogie B	2003	Br J Haematol2003，122，3：	1
4	Results of high-dose therapy for 1000 patients with multiple myeloma:durable complete remissions and superior survival in the absence of chromosome 13 abnormlities 显示文摘	Desikan R Barlogie B Sawyer J	2000	Blood2000，95，12：	1
5	A phase 2study of bortezomib in relapsed, refractory myelonm 显示文摘	Richardson P G Barlogie B Berenson J	2003	N Engl J Med2003，348，26：	1
6	Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling显示文摘	Zhan F Barlogie B Shaughnessy J Jr	2003	Semin Hematol2003，40，4：	1
7	Total therapy with tandem transplants for newly diagnosed multiple myeloma 显示文摘	Barlogie B Jagannath S Desikan KR	1999	Blood1999，93，1：	1
8	Thalidomide in the management of multiple myeloma 显示文摘	Barlogie B Yricot G Anaissie E		Semin0，，：	1
9	A phase 2 study of bortezomib in relapsed,refractory myeloma显示文摘	Richardson P Barlogie B Bremson J	2003	N Engl J Med2003，348，26：	1
10	Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials 显示文摘	DURIE B G JACOBSON J BARLOGIE B	2004	J Clin Oneol2004，22，10：	1
11	Total therapy 2 without thalidomide in comparison with total therapy 1:role of intensified induction and posttransplantation consolidation therapies显示文摘	Barlogie B Tricot G Rasmussen E	2006	Blood2006，107，7：	1
12	Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients显示文摘	Barlogie B Desikan R Eddlemon P	2001	Blood2001，98，2：	1
13	biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma显示文摘	BATAILLE R BARLOGIE B LU Z Y	1995	Blood1995，86，：	1
14	Extended survival in advanced and refractory multiple myeloma after single agent thalidomide:identification of prognostic factors in a phase 2 study of 169 patients显示文摘	Barlogie B Desikan R Eddlemon P	2001	Blood2001，98，2：	1
15	Genetics and cytogenetics of multiple myeloma:a workshop report显示文摘	Fonseca R Barlogie B Bataille R	2004	Cancer Res2004，64，：	1
16	Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone显示文摘	Jagannath S Richardson P G Barlogie B		0，，：	1
17	Increaseed risk of deep vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy 显示文摘	Zangari M Anaissie E Barlogie B	2001	Blood2001，98，5：	1
18	Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide:identification of prognostic factors in a phase 2 study of 169 patients显示文摘	Barlogie B Desikan R Eddlemon P	2001	Bood2001，98，2：	1
19	Treatment of multiple myeloma显示文摘	Barlogie B Shaughnessy J Tricot G	2004	Blood2004，103，：	1
20	Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma 显示文摘	BERENSON JR JAGANNATH S BARLOGIE B	2005	Cancer2005，104，10：	1

返回顶部每页显示：

共26页首页上一页第1页下一页末页 /26 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示